Pharmacology of 1, 2, 3, 4-tetrahydro-9-amino-acridine.
D000110:Acetylcholinesterase; D000166:Acridines / Q000494:pharmacology*; D000494:Allosteric Regulation; D000588:Amines / Q000494:pharmacology; D000818:Animals; D001561:Benzilates / Q000037:antagonists & inhibitors; D001665:Binding Sites / Q000187:drug effects; D002800:Cholinesterase Inhibitors / Q000494:pharmacology*; D002802:Cholinesterases; D003864:Depression, Chemical; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006321:Heart / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D066298:In Vitro Techniques; D007700:Kinetics; D009119:Muscle Contraction / Q000187:drug effects*; D010830:Physostigmine / Q000494:pharmacology; D011812:Quinuclidines / Q000037:antagonists & inhibitors; D051381:Rats; D013268:Stimulation, Chemical; D014403:Tubocurarine / Q000037:antagonists & inhibitors
D000166:Acridines; D000588:Amines; D001561:Benzilates; D002800:Cholinesterase Inhibitors; D011812:Quinuclidines; D010830:Physostigmine; D000110:Acetylcholinesterase; D002802:Cholinesterases; D014403:Tubocurarine